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Abstract
Although targeted therapies often elicit profound initial patient responses, these effects are 
transient due to residual disease leading to acquired resistance. How tumors transition between 
drug responsiveness, tolerance and resistance, especially in the absence of pre-existing subclones, 
remains unclear. In EGFR-mutant lung adenocarcinoma cells, we demonstrate that residual disease 
and acquired resistance in response to EGFR inhibitors requires AURKA activity. Non-genetic 
resistance through the activation of AURKA by its co-activator TPX2 emerges in response to 
chronic EGFR inhibition where it mitigates drug-induced apoptosis. Aurora kinase inhibitors 
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suppress this adaptive survival program, increasing the magnitude and duration of EGFR inhibitor 
response in pre-clinical models. Treatment induced activation of AURKA was associated with 
resistance to EGFR inhibitors in-vitro, in-vivo and in individuals with EGFR-mutant lung 
adenocarcinoma. These findings delineate a path whereby drug resistance emerges from drug-
tolerant cells and unveils a synthetic lethal strategy for enhancing responses to EGFR inhibitors by 
suppressing AURKA driven residual disease and acquired resistance.
MAIN
The approval and use of EGFR inhibitors in EGFR-mutant non-small cell lung cancer 
(NSCLC) has been a major clinical breakthrough helping to define the paradigm of precision 
medicine. However, EGFR tyrosine kinase inhibitors (EGFR-TKIs) often produce an 
incomplete response followed by progression and acquired resistance in 9–12 months, often 
a lethal event1–3. Disease progression occurs through tumor evolution upon treatment 
involving distinct genetic and non-genetic changes in cell state and signaling4. Furthermore, 
patient tumors develop acquired resistance via multiple mechanisms simultaneously5–8 and 
this polyclonal nature of resistance could limit the efficacy of approaches that target any 
single genetic driver of resistance. The heterogeneous nature of acquired resistance 
highlights the need to better understand and target residual disease, defined as the fraction of 
tumor cells that survive initial treatment and ultimately enable tumor progression in the 
presence of ongoing treatment9. Acquired resistance occurs through the selection of pre-
existing clones as well as evolution of drug-tolerant (i.e. persister) cells without genetic 
alterations that survive treatment through tumor cell adaptation that may involve the 
acquisition of genetic mutations later10–12. Both genetic and non-genetic forms of resistance 
to EGFR-TKIs have been identified including secondary mutations in EGFR, amplification 
of various receptor tyrosine kinases, transformation to small-cell lung cancer and epithelial-
mesenchymal transition (EMT)4,13–16. Third-generation EGFR inhibitors, rociletinib and 
FDA-approved agent osimertinib, bind and inhibit mutant EGFR with and without the 
T790M mutation, associated with resistance to previous generation EGFR inhibitors1,2. For 
these drugs, approximately half of acquired resistance cases have unknown genetic drivers 
and when genetic drivers exist, multiple drivers often co-occur in the same patient7,8,13. We 
identified a synthetic lethal interaction between EGFR-TKIs and Aurora kinase inhibitors in 
acquired resistant cells that has important implications for the development of new treatment 
strategies that are aimed at preventing rather than intercepting acquired resistance.
We modeled acquired resistance to both osimertinib and rociletinib by deriving polyclonal 
acquired resistant cell lines based on stepwise dose escalation over a period of 9 days 
followed by maintenance in 1uM of drug over 6 weeks (osimertinib resistant lines denoted –
OR and rociletinib lines –RR, Fig. 1a). We generated 8 acquired resistant models from 4 
different EGFR-mutant NSCLC cell lines including PC9, HCC827, HCC4006 and H1975 
which expresses a compound EGFR L858R and T790M mutation. There was a >10-fold 
change in IC50 in each line compared to parental and we observed cross-resistance between 
drugs indicating a shared mechanism of resistance regardless of which EGFR inhibitor used 
(Fig. 1b, Supplementary Fig. 1a). In response to TKI, resistant cells suppressed EGFR 
signaling and we observed no activation of alternate receptor tyrosine kinases previously 
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reported to facilitate bypass of EGFR inhibition (Supplementary Fig. 1b)17. In response to 
treatment, resistant cells demonstrated heightened ERK and AKT signaling and reduced 
apoptosis as measured by cleaved PARP compared to parental cells (Fig. 1c). Exome 
sequencing revealed no recurrent mutations among independently derived acquired resistant 
lines and no additional mutations in EGFR were detected (data not shown). We next sought 
to identify if these cells harbored markers of cell states known to be associated with 
resistance to EGFR-TKI. Compared to parental cells, resistant cells had an increase in 
Vimentin levels indicative of EMT, increased NF-κB signaling and minor changes in cancer 
cell stemness, all known to be associated with EGFR-TKI resistance (Supplementary Fig. 
1c)4,12,17–20. P53 and NRAS signaling were not strongly associated with resistance 
(Supplementary Fig. 1d,e)21,22. Heritability analysis using single cell clones indicated that 
the majority of cells derived from acquired resistant lines were re-sensitized to TKI after a 
period of drug withdrawal indicating a non-genetic and reversible mechanism of drug 
resistance (Supplementary Fig. 1f).
Based on the absence of any obviously targetable driver of resistance, we sought to identify 
pathways revealed by drugs that synergistically inhibit growth when combined with EGFR-
TKIs. Across a 94-compound cancer-focused library, both Aurora kinase inhibitors in the 
panel, AZD1152 and VX680, were the top synergistic candidates when combined with 2uM 
rociletinib in H1975-RR cells (Fig. 1d, Supplementary Table 1). The combination of these 
two agents as well as MLN8237, the most clinically advanced Aurora kinase inhibitor, with 
either osimertinib or rociletinib demonstrated synergistic reduction in cell growth in all 
models (Fig. 1e,f, Supplementary Fig 2a,b). Aurora kinase inhibitors display significant 
cross-reactivity between AURKA, AURKB and AURKC23. Therefore, these data reveal a 
primary requirement for Aurora kinase signaling in models of acquired resistance to third 
generation inhibitors of EGFR.
We sought to determine the relevant target of Aurora kinase inhibitors in driving drug 
synergy. Compared to parental cells, we found ~2-fold mRNA up-regulation but no increase 
in total protein levels for all three Aurora kinases in resistant cells (Fig. 2a, Supplementary 
Fig. 3a,b). In contrast, we found significant activation of AURKA, but not AURKB or 
AURKC, in resistant models as indicated by increased auto-phosphorylation at T288 (Fig. 
2a, Supplementary Fig. 3b). We next asked if activation of AURKA is sufficient to confer 
resistance to EGFR-TKI. AURKA activity peaks during G2/M phase of the cell cycle where 
it regulates chromosome alignment, mitotic spindle formation and chromosome 
segregation24. Parental PC9 cells synchronized using serum starvation or thymidine block 
into G2/M phase had high levels of phospho-AURKA, and were more viable and had 
diminished apoptosis in comparison to parental cells that were treated in G1/S or 
asynchronously (Supplementary Fig. 3c-i). Transient AURKA over-expression, but not 
AURKB, caused resistance to EGFR-TKIs at levels comparable to KRAS G12V, a known 
driver of resistance (Fig. 2b, Supplementary Fig. 3j)25.
AURKA can be activated by upstream factors which facilitate its auto-phosphorylation 
including TPX2, NEDD9, AJUBA and PAK126. We investigated each one and observed a 
consistent increase in TPX2 protein, and to a lesser extent transcription, and an increase in 
phospho-AURKA in all resistant models (Fig. 2c, Supplementary Fig. 4a,b). TPX2 activates 
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AURKA by locking it in an active conformation and protecting it from protein 
phosphatases24. Overexpression of TPX2 activated AURKA and caused resistance (Fig. 2b) 
whereas expression of other reported AURKA activators did not (Supplementary Fig. 4c,d). 
TPX2 is degraded by the ubiquitin E3 ligase Anaphase Promoting Complex bound to the 
specific activator CDH1 (APC/C) during mitotic exit and G1 phase27. By subcellular 
fractionation, we confirmed that CDH1 was nuclear in parental and resistant cells as 
expected28. In contrast, TPX2 was cytosolic in acquired resistant cells whereas in parental 
cells it was more likely to be nuclear (Supplementary Fig. 4e). Hence, TPX2 is not co-
localized with the complex responsible for its degradation in resistant cells. Together, these 
data suggest that altered TPX2 localization in acquired resistant cells contributes to AURKA 
activation during interphase and contributes to acquired resistance to 3rd generation EGFR-
TKIs.
We next sought to determine the mechanism of synergy focusing on MLN8237, the most 
advanced AURKA inhibitor (Fig. 1e,f). Combination treatment resulted in reduction in cell 
proliferation and increase in cell death measured by YO-PRO-1 positivity in acquired 
resistant models (Fig. 2d,e). In PC9-RR mouse xenografts, rociletinib partially abrogated 
tumor growth but rapidly progressed and the combination led to a stronger initial reduction 
in tumor growth which was sustained for 70 days (p=2.2e-11) (Fig. 2f). We observed no 
apparent toxicity based on body weight (Supplementary Fig. 5a). Similar results were also 
observed with osimertinib where the combination resulted in decrease tumor growth in 9 out 
of 10 tumors derived from PC9-OR cells (p=0.001, Fig. 2g, Supplementary Fig. 5b). To 
understand how AURKA might regulate apoptosis and proliferation we probed several 
signaling pathways known to be associated with resistance to EGFR inhibitors18,19,29. 
Combination treatment caused a decrease in ERK and NF-κB signaling, indicating multiple 
potentially overlapping routes through which AURKA signaling contributes to cell growth 
(Fig. 2h, Supplementary Fig. 6). Therefore the combination of EGFR and Aurora kinase 
inhibitors induce apoptosis and are synergistic in suppressing the growth of acquired 
resistant cells both in vitro and in vivo.
We next sought to understand the molecular mechanisms underlying how this combination 
engaged apoptotic machinery focusing on the pro-apoptotic factor BIM since its induction is 
essential for cell death induced by EGFR-TKIs30,31. BIM and its splice variant BIM-EL are 
regulated by phosphorylation leading to proteasomal degradation32. EGFR inhibition alone 
in parental PC9 cells suppressed phospho-BIM resulting in the accumulation of BIM-EL and 
induced PARP cleavage consistent with previous reports (Fig. 2h)30,31. In contrast, in 
resistant cells the combination of EGFR-TKI and MLN8237 was necessary to suppress 
phospho-BIM leading to the accumulation of BIM-EL, its primary effector BAX and 
cleaved PARP (Fig. 2h). In normal cells, AURKA suppresses apoptosis during mitosis by 
suppression of BIM24,33. Since acquired resistant cells expressed high levels of phospho-
AURKA throughout the cell cycle in contrast to parental cells (Supplementary Fig. 3d), 
these data indicate that resistant cells co-opt this natural function of AURKA for use 
throughout the cell cycle, thereby exploiting a redundancy in the control of BIM that is 
normally temporally segregated. Therefore acquired resistant cells escape from EGFR 
inhibition through a shift in the control of pro-apoptotic machinery from EGFR alone to 
both EGFR and AURKA (Fig. 2i).
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We next sought to elucidate the temporal processes leading to AURKA activation in 
acquired resistant cells. Based on our modeling after treatment we divided the period of drug 
response into three distinct phases: (1) a sensitive phase, (2) a drug tolerant phase where 
remaining cells persist and (3) a proliferative acquired resistance phase. We measured 
signaling dynamics across a time course of 9 days in H1975 cells treated with osimertinib 
and compared this with acquired resistant H1975-OR cells that were exposed for more than 
6 weeks (Fig. 3a). While osimertinib treatment inhibited EGFR throughout, we observed 
BIM-mediated apoptosis for two days after which it was suppressed indicating that the 
remaining cells were drug tolerant. In the sensitive phase, we observed a gradual increase in 
TPX2 followed by activation of AURKA peaking during drug tolerance and maintained into 
acquired resistance (Fig. 3b). These data indicate that AURKA activation emerges after 
chronic EGFR inhibition the formation of drug tolerant cells and acquired resistance.
Since high levels of TPX2 and AURKA cause mitotic errors and polyploidy34,35, we 
hypothesized that its abnormal levels should also leave a signature of defects associated with 
mitotic stress. We surveyed for mitotic defects induced by EGFR-TKI treatment and in 
acquired resistant cells. Seventy-two hour treatment with EGFR-TKI resulted in an 
accumulation of errors in centrosome biogenesis, spindle assembly and chromosome 
segregation in parental and acquired resistant models (Supplementary Fig. 7a,b, 
Supplemental Table 2) indicating persistent mitotic stress is a feature of EGFR inhibition. 
Upon EGFR inhibition, errors in mitosis lead to the generation of polyploid cells 
(Supplementary Fig. 7c) which were phenocopied by overexpression of AURKA or TPX2 in 
parental cells, implying causation (Supplementary Fig. 7d,e). These data indicate that 
acquired resistant cells emerge from drug-tolerant cells through the AURKA-dependent 
suppression of BIM, coincident with mitotic stress driven by abnormal levels of TPX2 and 
AURKA.
Because AURKA became activated during drug tolerance, we hypothesized that AURKA 
might also be necessary for the formation and survival of drug tolerant cells. While 
osimertinib and rociletinib drug tolerant persister cells12 maintained EGFR inhibition and 
suppressed BIM mediated apoptosis, they also displayed increased levels of phospho-
AURKA and TPX2 (Fig. 3c). This mechanism of tolerance to EGFR inhibition also 
observed with other EGFR inhibitors including erlotinib and afatinib (Fig. 3d). To determine 
if AURKA inhibition blocks the emergence of acquired resistance in EGFR-TKI naïve 
NSCLC cells, we treated single cell derived PC9 and H1975 cells with either single agent 
EGFR-TKI, MLN8237 or the combination over a period of 13 weeks and measured the rate 
of outgrowth of resistant clones. Combination treatments enhanced the magnitude of the 
response and delayed the emergence of resistance as compare to monotherapy (Fig. 3e,f). 
This was due to the combination increasing the proportion of cells displaying evidence of 
apoptosis over the course of treatment leading to a reduction in the formation of drug 
tolerant residual cells and was independent of which EGFR or Aurora kinase inhibitor was 
used (Fig. 3g, Supplementary Fig. 8a-c). Combination treatment was also effective in 
eradicating previously formed drug tolerant persister cells with near complete elimination 
within one week indicating that AURKA activity is necessary for their survival (Fig. 3h). 
These data suggest that the combination of EGFR-TKI and Aurora kinase inhibitors 
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administered simultaneously or in sequence at the time of residual disease may be an 
effective means to enhance the initial response and postpone acquired resistance.
We next explored the contribution of AURKA activation in clinical residual disease and 
progression. We tested an EGFR L858R positive and T790M negative patient-derived 
xenograft (PDX) tumor model from a residual mass obtained from a patient demonstrating 
an incomplete response to erlotinib19. Rociletinib treatment only modestly impaired tumor 
growth, indicating cross-resistance between erlotinib and rociletinib in this model. In 
contrast, the combination robustly decreased tumor growth compared to rociletinib alone 
(p=3.4e-4) and in most cases induced tumor regression with no observed toxicity based on 
weight (Fig. 4a, Supplementary Fig. 9a,b). Combination treatment induced apoptosis as 
evident by increased staining for cleaved Caspase-3 as well as loss of Ki67 staining in tumor 
tissue (Supplementary Fig. 9c,d). We also observed efficacy and lack of toxicity using 
osimertinib in combination with MLN8237 (p=6.6e-5, Fig. 4b, Supplementary Fig. 9e,f).
Consistent with our in vitro data, tumors treated with rociletinib for 30 days had lower 
phospho-EGFR levels and an increase in phospho-AURKA and TPX2 levels compared to 
vehicle alone (Fig. 4c). Enhanced TPX2 levels in rociletinib treated tumors was also evident 
through immuno-histochemistry (IHC) (Fig. 4d,e). EGFR suppression also induced mitotic 
stress in vivo, as there was a significant increase in the number of abnormal mitoses 
quantified via H&E staining (Supplementary Fig. 9g,h). The combination also induced 
apoptosis evidenced by suppression of phospho-BIM, increased total BIM and cleaved 
PARP compared to either single agent (Fig. 4c). These results provide mechanistic insights 
into processes occurring in vitro with those occuring at the point of residual disease and 
indicate that pharmacologically targeting AURKA at the point of maximal response or 
residual disease may be a viable clinical strategy to deepen responses.
We next sought to establish the clinical relevance of heightened TPX2/AURKA signaling in 
mediating acquired resistance to EGFR inhibition in NSCLC. Staining and automated 
quantification of TPX2 levels in matched diagnosis and relapse samples from 9 patients with 
advanced stage EGFR-mutant NSCLC who underwent treatment with erlotinib revealed a 
significant increase in TPX2 levels after acquired resistance as compared to pre-treatment 
(p=0.003, Fig. 4f). Using a threshold TPX2 score of 2 which was higher than what we 
observed in all 9 pre-treatment samples, we observed TPX2 positivity in 6 out of 9 cases 
(Fig 4g, Supplementary Fig. 10a). Interestingly, we observed increased TPX2 levels in three 
cases that were also EGFR T790M+ and another with MET amplification in the erlotinib 
resistant sample, suggesting that this non-genetic mechanism of resistance may co-occur 
with other genetic drivers of acquired resistance. In 3 acquired resistance cases to third 
generation inhibitors (two osimertinib and one rociletinib), all three were TPX2 positive and 
were increased compared to pre-treatment (p=0.02, Fig. 4h, Supplementary Fig. 10b). 
Together, resistance was associated with an increase in TPX2 regardless of EGFR-TKI used 
(p=2e-5, Fig. 4i). These data suggest that AURKA activation via TPX2 is a feature of most 
acquired resistant EGFR-mutant lung cancers regardless of therapy. We propose that TPX2 
could be used as a biomarker to select patients for combination therapy with an EGFR-TKI 
and an Aurora kinase inhibitor in EGFR-mutant lung adenocarcinoma.
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In summary, our findings have important implications for intercepting EGFR-TKI resistance 
in NSCLC patients, offering an alternative approach to combat the emergence of resistance. 
In light of observations that multiple distinct mechanisms of drug resistance can co-occur 
within the same patient at the time of relapse5–8, AURKA activation might co-occur with 
other factors driving resistance or could even provide a mechanism upon which such 
resistance-causing mutations could appear, giving rise to multiple genetically distinct 
clones11. The maintenance of residual disease by AURKA may provide a fertile ground for 
the formation of such resistance causing mutations, potentially through a late-emerging 
resistance model10,11. For example, mitotic abnormalities catalyzed by AURKA 
hyperactivity may give rise to gene amplifications that have been observed in patients 
progressing on EGFR inhibitors. Since mitotic errors lead to chromosomal instability 
contributing to disease progression and drug resistance36, resistance driven by AURKA may 
contribute to tumor heterogeneity and promote the generation of distinct clones harboring 
different genetic drivers of drug resistance. If correct, this adaptive response to EGFR 
inhibition could actually enhance tumor heterogeneity. We show AURKA contributes to a 
number of pathways and processes previously associated with resistance to EGFR inhibition 
including NF-κB, ERK and EMT26,37. Therefore it appears that AURKA is associated with 
a number of seemingly disparate mechanisms of acquired resistance, warranting further 
investigation.
Our results call for clinical trials testing the combination of Aurora kinase and EGFR 
inhibitors in EGFR-mutant lung adenocarcinoma, up front, at the point of residual disease, 
as well as after acquired resistance in tumors harboring high levels of TPX2. Patients 
progressing on first and third-generation EGFR-TKIs often have high levels of TPX2, 
indicating therapeutic relevance in a significant fraction of acquired resistant, 
immunotherapy refractory38 lung cancers. As single agent therapies, Aurora kinase 
inhibitors have reached phase III clinical trials39,40 and have non-overlapping toxicity 
profiles with EGFR inhibitors. We propose that the most effective use of this combination 
should be directed toward eliminating residual cancer cells before they acquire genetic 
mechanisms of resistance that could be polyclonal and heterogeneous in nature. While 
clinical studies will be necessary to determine the degree to which this combination strategy 
can delay the onset of resistance in patients, these results call to action a proactive paradigm 
aimed at preventing resistance rather than the current reactive paradigm of intercepting and 
treating drug resistance incrementally.
METHODS
Cell culture and compounds.
H1975, HCC827, and HCC4006 were from the American Type Culture Collection (ATCC). 
PC9 cells were a gift from Dr. F. Koizumi (National Cancer Center Research Institute and 
Shien-Lab, Tokyo, Japan). PC9 Parental cell line identity was confirmed by short-tandem 
repeat analysis (Genetica) and cells were used for no longer than 12 months before being 
replaced and were routinely tested for mycoplasma to ensure accuracy of experimental data. 
Rociletinib (CO-1686) was obtained from Clovis Inc. Erlotinib, afatinib and osimertinib 
(AZD9291) were purchased from Selleck Chemicals (Houston, TX USA).
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Generation of acquired resistant and drug tolerant cells.
Acquired resistant cells were derived by treating individual cell lines with increasing 
concentration of rociletinib or osimertinib starting at 50nM followed with a stepwise dose 
escalation every 48 hours up to 1uM. Acquired resistance cell lines derived by rociletinib 
treatment (PC9-RR, H1975-RR, HCC4006-RR, and HCC827-RR) or osimertinib treatment 
(PC9-OR, H1975-OR, HCC4006-OR, HCC827-OR) were maintained in 1μM of the 
respective drug. To generate drug tolerant persister cells parental PC9, H1975 were treated 
with 1 μM of erlotinib, afatinib, rociletinib and osimertinib for 9 days according to protocols 
described previously12. Cells were washed and replenished by fresh drug every 48 hrs.
Cell Proliferation/Apoptosis Assays.
Cell lines were seeded in 384-well assay plates at a density of 1,000 cells/well in a total 
volume of 40 μL/well, and incubated at 37°C, 5% CO2 overnight. Following drug exposure, 
proliferation was measured by staining with Hoechst 33422 (Life Technologies) nuclear dye 
and apoptosis using YO-PRO-1 (Life Technologies) early apoptosis dye and analyzed using 
a Thermo CellInsight high content microscope for indicated time. IC50 values were 
determined using GraphPad Prism 6.0. For drug synergy, fixed dose ratios were used to 
determine five different drug combinations. Following 72 hours of drug exposure, 
proliferation and cell death was measured by staining with Hoescht (Life Technologies) 
nuclear dye and YO-PRO-1 (Life Technologies), respectively, and analyzed using a Thermo 
CellInsight High Content microscope. Synergistic, additive, or antagonistic effects were 
determined using the combination index (CI) method of Chou and Talalay41.
Combinatorial drug screen.
H1975-RR cells were seeded in 384-well plates at a density of 1,000 cells/well in the 
presence of 2uM rociletinib or vehicle and after 24 hours exposed to three different doses of 
compounds from a 90-drug library for 72 hours. At the end of this period nuclei were stained 
with Hoechst 33422 (Life Technologies) and counted using a Thermo CellInsight high 
content microscope. The screen was repeated three times using varying library 
concentrations of 5 μg/mL, 500 ng/mL, and 50 ng/mL and each combination measured in 
quadruplicate. Raw cell numbers were median normalized on a per-plate basis. For each 
compound in the library, the relative cell number in the DMSO plate was compared with the 
number in the rociletinib plate using a Student’s t-test. A synergy score was developed based 
on the −log10 of the P value of this t-test and was signed to indicate synergistic inhibition of 
growth (positive score) or antagonism (negative score). The reported synergy score is based 
on the average of scores over three different library concentrations.
Clonogenic growth assay.
Colony outgrowth assays were performed via crystal violet staining and quantification. 
Briefly, cells were seeded in 12-well plates at a density of 1000 cells/well. Appropriate 
drugs were added after an additional 24 hr. Cells were exposed to drug or DMSO for 9–10 
days, with media change and fresh drug addition every 3 days. Cells were fixed with 4% 
formaldehyde and stained with 0.5% crystal violet. Pictures of stained cells were taken using 
EPSON Perfection V600. Growth was quantified by dissolving crystal violet in 0.1% SDS 
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and absorbance quantified at 590nm using a spectrophotometer and normalized to DMSO 
treatment.
Immunoblot.
Cells for immunoblots were harvested and lysed in lysis buffer containing 1 mol/L Tris-HCl, 
pH 7.6, 0.5 mol/L EDTA, 5 mol/L NaCl, 1% NP40, and 1% Triton X-100, supplemented 
with protease and phosphatase inhibitors (Calbiochem). Samples were sonicated and then 
centrifuged at 14,000 RPM for 10 minutes at 4°C. Protein concentrations were determined 
by Bradford assay (Bio-Rad). Equal amounts of protein (10–40ug) were loaded onto SDS-
PAGE gels, transferred to a PVDF membrane (Bio-Rad), and incubated with the indicated 
primary antibodies. Proteins were detected via incubation with HRP-conjugated secondary 
antibodies Clarity Western ECL Blotting Substrates (Bio-Rad) or SuperSignal West Femto 
Maximum Sensitivity Chemiluminescent Substrate (Thermo Fisher Scientific). Antibodies 
for pEGFR (Y1068; 3777), pERK1/2 (T202/Y204; 4370), ERK1/2 (9102), pAKT (S473; 
4060), AKT (9272), PARP (5625), pAURKA (T288; 3079), AURKA (4718) pRb (S780; 
9307), BIM (2933), pBIM (S69; 4585), BAX (5023), Vimentin (5741), p-p65 (S536; 3033), 
p65 (8242), Pan phospho-AURKA/B/C (T288/T232/T198; 2914), CD44 (3570), Histone H3 
(9715) were purchased from Cell Signaling Technology; TPX2 (HPA005487) and pan total 
AURKA/B/C (HPA002636) were purchased from Sigma; EGFR (SC-03), NEDD9 
(sc-33657), AJUBA (sc-398008), PAK1 (sc-16617), CD24 (sc-19585), CD133 (sc-30219), 
B-tubulin (sc-9104), p53 (sc-126) were purchased from Santa Cruz biotechnology and 
FZR1/CDH1 (ab3242) from Abcam and V5 tag (46–0705) from Thermofisher. Band 
intensities were quantified by Adobe Photoshop CS3. Phospho-RTK array were performed 
according to the manufacturer’s protocol (R&D systems, Minneapolis, MN USA).
Cell cycle synchronization and analysis.
For double thymidine block cells were seeded and 2mM thymidine was added and then later 
released from this block by washing the cells three times with PBS and adding complete 
media followed by second thymidine block and release. For synchronization using serum 
starvation and release, cells were kept in serum free media for 48hrs. For synchronizing cells 
in G1/S phase, cells were released for 2 hours and for synchronizing cells in G2/M phase, 
cells were released for 8 hours followed by drug treatment. In all cases the expected cell 
cycle was validated using FACS. For cell cycle analysis cells were fixed in cold ethanol and 
re-suspended in propidium Iodide (PI)/RNase Staining Solution (Cell Signaling 
Technology). After incubation for 15 minutes at room temperature in the dark, flow 
cytometric analysis was performed on a FACS AriaII cytometer (BD Biosciences). Flow 
cytometry data was analyzed by using FlowJo software to measure polyploidy (>4N).
Plasmid transfections.
LacZ, TPX2, AURKA, AURKB, AJUBA, NEDD9, PAK1 and KRAS G12V were obtained 
in a PLX304 backbone from Addgene (Cambridge, MA). 1ug/well of plasmids were 
transfected with 0.1% Fugene HD (Promega) for 48 hours before further analysis.
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Quantification of mitotic defects.
Cells were plated overnight on a tissue culture treated 8-well chamber slide (ThermoFisher). 
After 72-hour drug treatment, cells were washed with PBS and fixed by with ice-cold 
methanol at −20 C for 3 min. Following fixation, cells were permeabilized with PBS and 
0.1% Triton X-100 for 3 min, blocked in PBST (PBS, 5%BSA, 0.1% Triton X-100) for 30 
min, and then incubated with primary antibodies in blocking buffer for 90 min. Cells were 
washed with PBS and incubated with species-specific fluorescent secondary antibodies 
(Alexa-conjugated, Molecular Probes). DNA was stained with Hoechst 33342 (1:5,000; 
Invitrogen) for 5min in PBS. Coverslips were mounted with ProLong Anti-fade mounting 
medium (MolecularProbes). Antibodies were anti a-tubulin DM1a (1:500; Sigma-Aldrich 
T6199), anti y-tubulin (1:500; Sigma-Aldrich D00015). Images were collected with a Zeiss 
Cell Observer using the 404, 488 and 561nm laser.
Human tissue and immunohistochemistry.
All patient tumor samples analyzed were obtained under IRB-approved protocols with 
informed consent obtained from each subject under the guidance of the University of 
California, San Francisco. All relevant ethical regulations were followed. Mutational status 
of EGFR or other known drivers or resistance was determined using either FoundationOne 
(Foundation Medicine, Cambridge, MA) or UCSF pathology. Tissues were fixed in 10% 
formalin overnight and embedded in paraffin. Tissue sections of patient derived xenograft 
and patients samples were sectioned on slides with 4-μm thickness. The paraffin sections 
were de-paraffinized in xylene and rehydrated in a graded alcohol series, boiled with 10 
mmol/L of citrate buffer (pH 6) for 10 min, and treated with 0.3% H2O2 for 10 min. The 
steps were performed using the envision two-step method using the Envision and DAB 
Color kit (Gene Tech Company Limited, Shanghai). The TPX2 antibody (Sigma 
HPA005487, 1:200 dilution), cleaved-caspase-3 (#9661, Cell Signaling Technologies, 1:200 
dilution), the mouse monoclonal antibody Ki67 (KI67-MM1-L-CE, Leica Microsystems, 
1:100 dilution), were used, and PBS was used as a negative control. Images were captured 
using Zeiss AxioImager M1 and immunoreactivity was evaluated IHC profiler42 as an Image 
J plug-in in blinded manner. The evaluation was based on the staining intensity and extent of 
staining. The staining area was scored using the following scale, 0: 0–10%, 1: 10–20% of 
tissue stained positive, 2: 20–40% stained positive, 3: 40–70% stained positive and 4: > 70% 
positive cells. The sum of staining score (intensity + extension) index was designated as 
follows, 0–2: negative expression, 3–4: strong expression. IHC score was generated from 3 
different areas of the slides and average score was calculated for each sample.
Mouse xenograft studies.
Cell line xenograft experiments were performed in female C.B-17 SCID mice age 8 weeks 
by injecting 5 X 106 PC9-RR, PC9-OR tumor cells within 50% matrigel. Tumors were 
allowed to grow until they reached a minimum volume of 150 mm3 and mice were 
randomized to receive treatment by oral gavage seven days per week for 71 days. Rociletinib 
was formulated using 5% DMSO, 15% Solutol HS15 (Sigma Inc) in 80% water and 
osimertinib was formulated in 1% DMSO, 30% PEG300 and 69% water. MLN8237 was 
formulated using 10% (2-Hydroxypropyl)-β-cyclodextrin in water. Tumor growth was 
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assessed twice weekly by caliper measurements. A minimum of 10 tumors per treatment 
group were assessed for the duration of the study. For PDX xenografts, patient derived tumor 
cells were engrafted subcutaneously into the flank C.B-17 SCID mice. Tumors were allowed 
to grow until they reached a minimum volume of 200 mm3 and then randomly placed into 
control or treatment groups. Animals were treated daily for 30 days via oral gavage and 
tumor volume was calculated daily using caliper measurement. Percentage change for tumor 
growth was based on volumes calculated from size on day 1 at the beginning of treatment. 
All animal studies were conducted in accordance with the UCSF Institutional Animal Care 
and Use Committee (IACUC) and all relevant ethical regulations were followed.
Real time PCR.
RNA was isolated according to the manufacturer’s instructions (TRIzol, Life Technologies). 
One microgram of total RNA from each sample was subjected to first-strand cDNA 
synthesis according to the manufacturer’s recommendations (Promega). Quantitative PCR 
was performed on a CFX96 Real-Time PCR detection system with a PrimeTime Gene 
Expression Master Mix (IDT technology) according to the manufacturer’s protocol. TPX2 
was amplified with the following primers: 5′-AGGGGCCCTTTGAACTCTTA-3′ (forward 
primer) and 5′-TGCTCTAAACAAGCCCCATT-3′ (reverse primer). RPL13A was used as 
an endogenous control with the following primers: 5′-CGGATTTGGTCGTATTGG-3′ 
(forward primer) and 5′-TCCTGGAAGATGGTGATG-3′ (reverse primer). AURKA was 
amplified with following forward primer for AGTTGGCAAACGCTCTGTCT (forward 
primer) and GTGCCACACATTGTGGTTCT (reverse primer). AURKB was amplified using 
TCCCTGTTCGCATTCAACCT (forward primer) and GTCCCACTGCTATTCTCCATCAC 
(reverse primer). AURKC was amplified ACAACACCGGAACATCCTTC (forward primer) 
and TGCTGGTCCAACTTCTGATG (reverse primer). The cycling conditions for TPX2, 
AURKA, AURKB and AURKC and RPL13A were as follows: one cycle at 95°C for 3 min, 
40 cycles of 95°C for 15 s, and 60°C for 60 s. The specificity of the PCR amplification was 
validated by the presence of a single peak in the melting curve analyses. Each RT-qPCR 
experiment was repeated three times.
In-vitro resistance assay
Single cell expanded PC9 and H1975 cells were plated in 96-well plates at a density of 500 
cells per well (~10% confluency), and drug treatments began the following day. Each 
treatment group had 12 replicates, and drug was replaced every 72–96 hr. Each plate was 
harvested at the end of day 1,3,5,10,15,20,30,45,60,75 and 90 and cell proliferation 
measured.
Reversibility of resistance
To test the reversibility of resistance, we seeded single cell clones using limited dilution 
method into 384-well plates. Single cell clones were allowed to expand in absence or in 
presence of drugs for 14 days. Once these single cells achieved about 80% confluence at the 
end of 14 days, a subset that were expanded in the absence of drug were tested for the 
sensitization by adding 1uM of respective EGFR-TKI for 72 hours. For each cell line 96 
single cell clones were analyzed in each treatment condition.
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RasGTP Pull-down Assay
Cells were washed twice in ice-cold PBS and lysed in 1% TX100-TNM lysis buffer (20 
mmol/L Tris pH 7.5, 5 mmol/L MgCl2, 150 mmol/L NaCl, 1% Triton X-100) supplemented 
with 1 mmol/L DTT, and protease and phosphatase inhibitors (SigmaAldrich). Equal 
amounts of protein from each sample were added to 10 ¼L of packed GST-Raf-RBD or Ral-
GDS-RBD beads in 300 to 500 ¼L of 1% TX100-TNM lysis buffer and rotated at 4°C for 1 
to 2 hours. Beads were washed 3 times with 1 mL of cold lysis buffer and boiled in lithium 
dodecyl sulfate (LDS) sample buffer (Invitrogen).
Subcellular Fractionation
Nuclear and cytoplasmic fractions were prepared using the NE-PER Nuclear and 
Cytoplasmic Extraction reagents (Thermo Scientific) as per manufacturer’s instruction. 
Protein concentration was quantitated using the BCA protein assay kit (Pierce). Equal 
amounts of protein were loaded in each lane and separated on a 4–12% Bis-Tris gel 
(Invitrogen), then transferred onto a nitrocellulose membrane.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. EGFR mutant lung adenocarcinoma cells demonstrating acquired resistance to third-
generation EGFR tyrosine kinase inhibitors are sensitive to Aurora kinase inhibition.
a Schematic of cell number throughout the process to generate acquired resistant EGFR 
mutant lung adenocarcinoma cell lines through continuous cell culture and stepwise dose 
escalation of either osimertinib or rociletinib from 10 nM to 1 uM over the course of 9 d. 
Cell lines and EGFR mutation are listed. b Mean relative proliferation of parental, 
osimertinib (denoted -OR) and rociletinib (denoted -RR) acquired resistant cell lines treated 
with the indicated agents and allowed to proliferate for 3 d. IC50 analysis of dose–response 
curves from n = 4 biologically independent samples. The IC50 for each cell line is indicated 
in parenthesis. c Immunoblot analysis showing activity of the EGFR, AKT and ERK as well 
as PARP cleavage in response to 24 h treatment (+) or not (−) with DMSO, osimertinib 
(1uM) or rociletinib (1uM) in parental or acquired resistant cell lines. Actin is loading 
control. cl. PARP = cleaved PARP. Experiment was perfomed twice with similar results. d 
Sorted results from a combinatorial drug screen across 94 drugs combined with 2uM 
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rociletinib in H1975-RR cells. Synergy based on enhancement of growth inhibition 
compared to either drug along (see Methods). Screen was performed once. e Crystal violet 
staining of parental and osimertinib acquired resistant cell lines or f rociletinib acquired 
resistant cell lines 9 d after treatment with DMSO or the indicated drugs. Aurora kinase 
inhibitors are annotated with their relative targets in order of potency. Quantification 
(relative number of stained cells) is shown on the bottom right. c,e,f are representative of 
two independent experiments. Error bars are s.e.m. Full blots are shown in Supplementary 
Fig. 11.
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Figure 2. Activation of Aurora Kinase A is sufficient to cause resistance to EGFR-TKI and drug 
combinations induce apoptosis through BIM upregulation in vitro and in vivo.
a Immunoblot analysis of total and phosphorylated AURKA in PC9 and H1975 parental and 
acquired resistant cell lines treated with 1uM of the indicated inhibitors for 24 h. b Mean of 
cell proliferation of PC9 or H1975 cells transfected with plasmids expressing the indicated 
genes and treated 1uM EGFR-TKI for 72 h compared to DMSO treated cells performed in 
n=3 biologically independent samples. Significance based on comparison to LacZ control. c 
Immunoblot analysis 4 parental and 8 acquired resistant cell lines. Quantified intensities for 
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pAURKA and TPX2 relative to the parental cell line is shown. d Proliferation compared to 
DMSO of PC9 and H1975 parental or acquired resistant cells treated with 1uM of 
osimertinib or rociletinib, 30nM of MLN8237 or the combination for 72 h. Mean over n=3 
biologically independent samples. e Apoptosis measured by YO-PRO-1 positivity in the 
same models and drug treatments for 72 h. Shown is mean from n=3 biologically 
independent samples. f Mean tumor volume (mm3) of PC9-RR xenografts during treatment 
with rociletinib (100mg/kg), MLN8237 (10mg/kg) or the combination. n=10 tumors in the 
vehicle and rociletinib arm, and n=7 in the MLN8237 and combination arm. g Percent 
change in tumor volume compared to baseline for individual PC9-OR cell xenografts teated 
for 11 days with osimertinib (5mg/kg), MLN8237 (10mg/kg) or the combination. P-value 
comparing combo to single agent osimertinib treatment. h Immunoblot of lysates from 
parental PC9, PC9-OR and PC9-RR cells treated with the indicated inhibitors or DMSO for 
24 h. i Proposed mechanism for the efficacy of the combination in acquired resistant cells. P-
values based two-tailed Student’s t-test. Error bars represent s.e.m. Blots are representative 
of at least two independent experiments. Full blots shown in Supplementary Fig. 11.
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Figure 3. EGFR inhibition leads to the activation of TPX2 and AURKA during drug tolerance 
where it is necessary for survival and emergence of acquired resistance in vitro.
a Immunoblot of lysates from H1975 cells treated with osimertinib between 0 and 9 days 
and in H1975 osimertinib acquired resistant cells (H1975-OR) which have undergone 
continual treatment for >6 weeks. b Quantification of the indicated molecules in (a) 
normalized to actin and scaled by maximal intensity. c Immunoblot of indicated molecules 
lysates from drug tolerant PC9 or H1975 cells that persist after treatment with 1uM of the 
indicated agents for 9 d or in the parental cell line. d Immunoblot of PC9 drug tolerant 
persister (DTP) cells formed by treatment with 1uM of EGFR inhibitors erlotinib (first 
generation), afatinib (second generation), rociletinib or osimertinib (both third generation) 
for 9 d. e Growth of PC9 or H1975 cells in culture over time after plating and treated with 
the indicated drugs. Shown is mean over n=4 biologically independent samples per time 
point. f Time to resistance defined as days to reach exponential growth in various treatment 
conditions. n.a. = resistance not achieved after 90 d. g Clonogenic growth of PC9 and H1975 
cells treated with either 1uM rociletinib or the combination of rociletinib and 30nM 
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MLN8237 for 9 d. Images represents n=2 independent experiments. h Drug tolerant 
persister PC9 or H1975 cells were generated through 9 d of treatment with 1uM of 
osimertinib or rociletinib and then exposed to either 1uM EGFR-TKI alone or with that 
addition of 30nM MLN8237 for up to 7 d. Shown is mean of percent cells remaining relative 
to day 0 calculated from n=4 biologically independent samples per time point. Error bars 
s.e.m. c,d are representative images of at least two independent experiments. Full blots 
shown in Supplementary Fig. 11.
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Figure 4. Clinical potential of combined EGFR and Aurora kinase inhibition on residual disease 
and acquired resistance.
a Growth of patient derived xenograft derived from a patient with an EGFR L858R mutant 
lung adenocarcinoma displaying an incomplete response to erlotinib biopsied at the point of 
residual disease. Mice were treated with 100mg/kg rociletinib, 10mg/kg MLN8237 or the 
combination of rociletinib and MLN8237 for 30 d. P-value based on comparison of 
combination to rociletinib alone. Shown are averages over six tumors per arm. b Growth of 
individual PDX tumors treated 1mg/kg osimertinib, 10mg/kg MLN8237 or the combination 
for 30 d. P-value based on comparison of combination to osimertinib alone. Shown are 
averages over four tumors the osimertinib arm and six tumors in all others. c Immunoblot of 
lysates from individual PDX tumors harvested 30 d after the initiation of treatment with the 
indicated compounds. cl. PARP = cleaved PARP. Images represents n=4 independent tumors 
and was performed once. d Mean TPX2 levels from PDX tumors based on quantification of 
immunohistochemical (IHC) staining. e Representative image of TPX2 IHC from PDX 
Shah et al. Page 21
Nat Med. Author manuscript; available in PMC 2019 May 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
tumors treated with the indicated agents. Images taken at 20× magnification. Scale bar, 
100¼M. Data representative of six independent tumors. f Mean TPX2 IHC scores from 9 
matched tumor samples from EGFR-mutant lung adenocarcinoma patients taken at the time 
of diagnosis and at the time of relapse to erlotinib. g TPX2 IHC score of patient tumor tissue 
obtained before (ending with A) and upon relapse on erlotinib (ending with B). Same 
numbers indicate tumors from same patient. Known genetic drivers of resistance based on 
genomic analysis are indicated. h Quantification of TPX2 IHC scores from human tumor 
samples taken from EGFR-mutant lung adenocarcinoma patients at the time of diagnosis 
(ending with the letter A) and at the time of relapse after treatment with either osimertinib or 
rociletinib (ending with letter B). i Mean TPX2 IHC score from all tumors taken from 
EGFR-mutant lung adenocarcinoma patients before treatment and after resistance to the 
indicated TKIs. All plots are mean with error bars as s.e.m. in panels a and b, and s.d. in 
panels d,f and i. P-values based two-tailed Student’s t-test. Full blot images are shown in 
Supplementary Fig. 11.
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